That's because the guy has a worthless "arts" degree and knows nothing about medical sciences. Our nutsy professor should be the one analyzing bio-techs imo.
Let see some traders get out and the stock continues down from that exit point but they are fools? It's not about the article' content nor about the author. It's about preception. Now if I choose to re-enter at a lower pps I have that option.